Chord Energy Corporation Announces Expiration of Cash Tender Offer for its Outstanding 6.375% Senior Notes Due 2026
HOUSTON, March 10, 2025 /PRNewswire/ — Chord Energy Corporation (the “Company,” “we,” “us,’ or “our”), today... Read more.
DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Boart Longyear Group, Ltd. Customers Whose Data May Have Been Compromised
NEWTOWN, Pa., March 10, 2025 /PRNewswire/ — Edelson Lechtzin LLP, a national class action law firm, is investigating claims regarding data privacy violations... Read more.
CoreWeave Announces Agreement with OpenAI to Deliver AI Infrastructure
CoreWeave to provide dedicated compute capacity for OpenAI’s model training and services LIVINGSTON, N.J., March 10, 2025 /PRNewswire/ — CoreWeave today... Read more.
Ivim Health Supports the Outsourcing Facilities Association’s Appeal of Court Ruling That Further Restricts Access to Compounded GLP-1 Medications
Recent Federal Court Ruling Denying Request for an Injunction Will Endanger Patients by Limiting Access to Critical Weight Loss & Diabetes Drugs COLUMBUS, Ohio,... Read more.
Hesai Selected by Top European OEM For Exclusive Multi-Year Lidar Contract On Its Next-Generation Global Platform
PALO ALTO, Calif., March 10, 2025 /PRNewswire/ — Hesai Technology (NASDAQ: HSAI), the global leader in lidar technology for automotive mobility and robotics... Read more.
Novolex Announces Cash Tender Offer for 7.950% Debentures due 2025 of Pactiv LLC
CHARLOTTE, N.C., March 10, 2025 /PRNewswire/ — Novolex Holdings, LLC (“Novolex” or the “Offeror“) announced today its offer to purchase... Read more.
Ultra Maritime Australia to provide world leading sonar on Hunter class frigates
ADELAIDE, South Australia, March 10, 2025 /PRNewswire/ — The Royal Australian Navy’s Hunter class frigates will be fitted with Ultra Maritime’s... Read more.
Drug Launch Strategy Analysis: Success Story of Identifying First Launch, Timelines, and Geographies Through Primary Intelligence
A Germany-based mid-sized pharma company actively engaged in the late-stage development of a therapy for Primary Immunodeficiency (PID) and, with a strong marketing... Read more.
BAVENCIO Continues to Strengthen Its Position in the Immuno-Oncology Landscape | DelveInsight
With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO’s market growth is driven by expanding indications and strategic partnerships.... Read more.
Broadway Financial Corporation Announces New Board Member
LOS ANGELES, March 10, 2025 /PRNewswire/ — Broadway Financial Corporation (“Broadway” or the “Company”) (NASDAQ: BYFC), parent company... Read more.